Mixed-Backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects
- 1 November 1998
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 8 (22) , 3269-3274
- https://doi.org/10.1016/s0960-894x(98)00591-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Mixed Backbone Oligonucleotides: Improvement in Oligonucleotide-induced Toxicity In VivoAntisense and Nucleic Acid Drug Development, 1998
- Pharmacokinetics and Metabolism of an Oligodeoxynucleotide Phosphorothioate (GEM91®) in Cynomolgus Monkeys Following Intravenous InfusionAntisense and Nucleic Acid Drug Development, 1998
- Effects of synthetic oligonucleotides on human complement and coagulation∗Biochemical Pharmacology, 1997
- Mixed backbone oligonucleotides containing internucleotidic primary phosphoramidate linkagesBioorganic & Medicinal Chemistry Letters, 1996
- Synthesis, biophysical properties, and stability studies of mixed backbone oligonucleotides containing segments of methylphosphotriester internucleotidic linkagesTetrahedron, 1996
- Antisense oligonucleotides: towards clinical trialsTrends in Biotechnology, 1996
- Hybrid oligonucleotides: Synthesis, biophysical properties, stability studies, and biological activityBioorganic & Medicinal Chemistry, 1996
- Effect of different chemically modified oligodeoxynucleotides on immune stimulationBiochemical Pharmacology, 1996
- In vivo stability, disposition and metabolism of a “hybrid” oligonucleotide phosphorothioate in ratsBiochemical Pharmacology, 1995
- Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-o- methyloligoribonucleotidesBioorganic & Medicinal Chemistry Letters, 1994